Experimental cell therapy targets Tough-to-Treat cancers
Disease control
Recruiting now
This early-stage study is testing the safety and initial effectiveness of a new cell therapy called anti-HER2 CAR-T in patients with advanced HER2-positive solid tumors that haven't responded to standard treatments. Researchers will give patients modified immune cells designed to…
Phase: NA • Sponsor: UTC Therapeutics Inc. • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC